vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and VIRTUS INVESTMENT PARTNERS, INC. (VRTS). Click either name above to swap in a different company.
VIRTUS INVESTMENT PARTNERS, INC. is the larger business by last-quarter revenue ($208.0M vs $168.4M, roughly 1.2× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -10.9%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -3.2%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
VIRTUS INVESTMENT PARTNERS, INC.VRTSEarnings & Financial Report
Virtus Investment Partners, Inc. is an American company which operates as a multi-manager asset management business, comprising a number of individual affiliated managers, each having its own investment process and brand, and the services of unaffiliated sub advisers.
ESPR vs VRTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $208.0M |
| Net Profit | — | $33.9M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | 19.1% |
| Net Margin | — | 16.3% |
| Revenue YoY | 143.7% | -10.9% |
| Net Profit YoY | — | -14.2% |
| EPS (diluted) | $0.32 | $5.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $208.0M | ||
| Q3 25 | $87.3M | $216.4M | ||
| Q2 25 | $82.4M | $210.5M | ||
| Q1 25 | $65.0M | $217.9M | ||
| Q4 24 | $69.1M | $233.5M | ||
| Q3 24 | $51.6M | $227.0M | ||
| Q2 24 | $73.8M | $224.4M | ||
| Q1 24 | $137.7M | $222.0M |
| Q4 25 | — | $33.9M | ||
| Q3 25 | $-31.3M | $31.3M | ||
| Q2 25 | $-12.7M | $42.7M | ||
| Q1 25 | $-40.5M | $28.1M | ||
| Q4 24 | — | $39.5M | ||
| Q3 24 | $-29.5M | $49.1M | ||
| Q2 24 | $-61.9M | $26.0M | ||
| Q1 24 | $61.0M | $37.9M |
| Q4 25 | 50.6% | 19.1% | ||
| Q3 25 | -11.4% | 21.7% | ||
| Q2 25 | 8.6% | 21.5% | ||
| Q1 25 | -34.0% | 16.8% | ||
| Q4 24 | -6.4% | 21.7% | ||
| Q3 24 | -31.0% | 24.3% | ||
| Q2 24 | 3.5% | 19.7% | ||
| Q1 24 | 52.5% | 14.5% |
| Q4 25 | — | 16.3% | ||
| Q3 25 | -35.9% | 14.5% | ||
| Q2 25 | -15.4% | 20.3% | ||
| Q1 25 | -62.2% | 12.9% | ||
| Q4 24 | — | 16.9% | ||
| Q3 24 | -57.2% | 21.6% | ||
| Q2 24 | -83.9% | 11.6% | ||
| Q1 24 | 44.3% | 17.1% |
| Q4 25 | $0.32 | $5.15 | ||
| Q3 25 | $-0.16 | $4.65 | ||
| Q2 25 | $-0.06 | $6.12 | ||
| Q1 25 | $-0.21 | $4.05 | ||
| Q4 24 | $-0.14 | $4.65 | ||
| Q3 24 | $-0.15 | $5.71 | ||
| Q2 24 | $-0.33 | $2.43 | ||
| Q1 24 | $0.34 | $4.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | — |
| Total DebtLower is stronger | — | $390.0M |
| Stockholders' EquityBook value | $-302.0M | $934.0M |
| Total Assets | $465.9M | $4.3B |
| Debt / EquityLower = less leverage | — | 0.42× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | — | ||
| Q3 25 | $92.4M | — | ||
| Q2 25 | $86.1M | — | ||
| Q1 25 | $114.6M | — | ||
| Q4 24 | $144.8M | — | ||
| Q3 24 | $144.7M | — | ||
| Q2 24 | $189.3M | — | ||
| Q1 24 | $226.6M | — |
| Q4 25 | — | $390.0M | ||
| Q3 25 | — | $390.6M | ||
| Q2 25 | — | $231.3M | ||
| Q1 25 | — | $231.7M | ||
| Q4 24 | — | $232.1M | ||
| Q3 24 | — | $237.5M | ||
| Q2 24 | — | $247.6M | ||
| Q1 24 | — | $253.0M |
| Q4 25 | $-302.0M | $934.0M | ||
| Q3 25 | $-451.4M | $918.7M | ||
| Q2 25 | $-433.5M | $896.4M | ||
| Q1 25 | $-426.2M | $893.7M | ||
| Q4 24 | $-388.7M | $897.5M | ||
| Q3 24 | $-370.2M | $889.0M | ||
| Q2 24 | $-344.2M | $868.7M | ||
| Q1 24 | $-294.3M | $871.7M |
| Q4 25 | $465.9M | $4.3B | ||
| Q3 25 | $364.0M | $3.9B | ||
| Q2 25 | $347.1M | $3.7B | ||
| Q1 25 | $324.0M | $3.7B | ||
| Q4 24 | $343.8M | $4.0B | ||
| Q3 24 | $314.1M | $3.6B | ||
| Q2 24 | $352.3M | $3.6B | ||
| Q1 24 | $373.1M | $3.5B |
| Q4 25 | — | 0.42× | ||
| Q3 25 | — | 0.43× | ||
| Q2 25 | — | 0.26× | ||
| Q1 25 | — | 0.26× | ||
| Q4 24 | — | 0.26× | ||
| Q3 24 | — | 0.27× | ||
| Q2 24 | — | 0.29× | ||
| Q1 24 | — | 0.29× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $-67.2M |
| Free Cash FlowOCF − Capex | — | $-74.1M |
| FCF MarginFCF / Revenue | — | -35.6% |
| Capex IntensityCapex / Revenue | 0.0% | 3.3% |
| Cash ConversionOCF / Net Profit | — | -1.99× |
| TTM Free Cash FlowTrailing 4 quarters | — | $100.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $-67.2M | ||
| Q3 25 | $-4.3M | $108.3M | ||
| Q2 25 | $-31.4M | $75.8M | ||
| Q1 25 | $-22.6M | $-3.8M | ||
| Q4 24 | $-35.0M | $1.8M | ||
| Q3 24 | $-35.3M | $69.1M | ||
| Q2 24 | $-7.2M | $70.0M | ||
| Q1 24 | $53.8M | $-34.5M |
| Q4 25 | — | $-74.1M | ||
| Q3 25 | — | $106.9M | ||
| Q2 25 | — | $74.2M | ||
| Q1 25 | — | $-6.8M | ||
| Q4 24 | — | $-3.8M | ||
| Q3 24 | $-35.5M | $68.7M | ||
| Q2 24 | $-7.3M | $68.6M | ||
| Q1 24 | $53.8M | $-36.5M |
| Q4 25 | — | -35.6% | ||
| Q3 25 | — | 49.4% | ||
| Q2 25 | — | 35.2% | ||
| Q1 25 | — | -3.1% | ||
| Q4 24 | — | -1.6% | ||
| Q3 24 | -68.7% | 30.3% | ||
| Q2 24 | -9.9% | 30.6% | ||
| Q1 24 | 39.0% | -16.4% |
| Q4 25 | 0.0% | 3.3% | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | 0.0% | 0.7% | ||
| Q1 25 | 0.0% | 1.4% | ||
| Q4 24 | 0.0% | 2.4% | ||
| Q3 24 | 0.3% | 0.2% | ||
| Q2 24 | 0.1% | 0.6% | ||
| Q1 24 | 0.1% | 0.9% |
| Q4 25 | — | -1.99× | ||
| Q3 25 | — | 3.45× | ||
| Q2 25 | — | 1.77× | ||
| Q1 25 | — | -0.13× | ||
| Q4 24 | — | 0.04× | ||
| Q3 24 | — | 1.41× | ||
| Q2 24 | — | 2.69× | ||
| Q1 24 | 0.88× | -0.91× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
VRTS
| Open End Funds | $68.9M | 33% |
| Retail Separate Accounts | $51.3M | 25% |
| Institutional Accounts | $39.6M | 19% |
| Administration And Shareholder Service Fees | $18.4M | 9% |
| Closed End Funds | $15.9M | 8% |
| Distribution And Service Fees | $12.3M | 6% |
